Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

spinal muscular atrophy

Orphan drugs: the early access regulatory environment

Despite considerable variation to the rules for unlicensed orphan drugs, there are some clear first steps for a global access programme

- PMLiVE

Novartis adds Facebook personalisation to sight campaign

Features the viewer's own pictures from the social network

Novartis building

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Intermune supports awareness efforts for IPF

Last week's IPF World Week saw the global patient community unite

- PMLiVE

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

China flag thumb

Novartis’ Alcon unit diverted trial money for bribes, claims paper

21st Century Business Herald publishes more allegations of corruption in China

- PMLiVE

Personalised understanding: oncology and orphan diseases

Improvements in our understanding of cancer are drawing the orphan drug and oncology worlds ever closer together

Harnessing social media for campaign success

Digital excellence from Ruder Finn's meningitis work for Novartis

Novartis building

Novartis signs cell therapy deal with Regenerex

Involves platform that could allow transplant patients to live without lifelong immunosuppression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links